Patent ID: 7468357

Claim:
A method of treating a patient infected with hepatitis B virus and HIV comprising administering to the patient a nucleotide prodrug of β-L-2′,3′-dideoxyadenosine (β-L-DDA) in combination with a second compound selected from: a) 3′-azido-3′-deoxythymidine (AZT), b) 2′,3′-dideoxyinosine (DDI), c) 2′,3′-dideoxy-2′,3′-didehydrothymidine (D4T), d) 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (FTC), e) a Tibo compound, nevirapine, or a pyrimidinone, or f) a physiologically acceptable salt thereof.